All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On November 9, 2023, quizartinib, an oral selective type II FLT3 inhibitor, was approved by the European Commission (EC) in combination with standard cytarabine and anthracycline induction, standard cytarabine consolidation chemotherapy, and as a maintenance monotherapy for the treatment of adult patients with newly diagnosed FLT3-ITD-mutated acute myeloid leukemia.1
This approval is based on a recent positive opinion by the European Medicines Agency’s Committee of Medicinal Products for Human Use, previously covered by the AML Hub, and results from the QuANTUM-First trial (NCT02668653).1 Quizartinib has also been approved by the U.S. Food and Drug Administration and in Japan for the same indication.
Subscribe to get the best content related to AML delivered to your inbox